| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454574 | Lung Cancer | 2016 | 5 Pages |
Abstract
Weekly nab-paclitaxel was associated with acceptable toxicity and a favorable ORR in previously treated patients with advanced NSCLC. Our results justify the undertaking of a phase III trial comparing nab-paclitaxel with docetaxel in this patient population.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Shinya Sakata, Sho Saeki, Isamu Okamoto, Kohei Otsubo, Kazutoshi Komiya, Ryotaro Morinaga, Yasuto Yoneshima, Yuichiro Koga, Aimi Enokizu, Hiroto Kishi, Susumu Hirosako, Emi Yamaguchi, Naoko Aragane, Shinji Fujii, Taishi Harada, Eiji Iwama, Hiroshi Semba,